Compare VIR & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | MEG |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | 3500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 930.8M |
| IPO Year | 2019 | 2020 |
| Metric | VIR | MEG |
|---|---|---|
| Price | $9.07 | $21.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $19.63 | ★ $35.25 |
| AVG Volume (30 Days) | ★ 4.4M | 422.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.49 | ★ 93.69 |
| EPS | N/A | ★ N/A |
| Revenue | $68,556,000.00 | ★ $830,538,000.00 |
| Revenue This Year | N/A | $5.46 |
| Revenue Next Year | $1,049.62 | $7.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.26 |
| 52 Week Low | $4.16 | $10.51 |
| 52 Week High | $10.91 | $32.00 |
| Indicator | VIR | MEG |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 35.09 |
| Support Level | $8.67 | $21.00 |
| Resistance Level | $10.29 | $24.03 |
| Average True Range (ATR) | 0.52 | 1.19 |
| MACD | -0.12 | -0.63 |
| Stochastic Oscillator | 24.69 | 1.40 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.